Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma
Description
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. MeSH
Hierarchy View
Subtype Terms (2)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
258 drugs (134 approved, 124 experimental)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
47 drugs (28 approved, 19 experimental)
Approved Indicated Drugs (16)
Phase 2 Indicated Drugs (79)
cd45-depleted allogenic peripheral blood stem cell
cord blood hematopoietic stem cell
gemtuzumab ozogamicin (mylotarg)
Phase 1 Indicated Drugs (95)
90Yttrium-labelled Anti-CD66 Monoclonal Antibody
allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes
allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
cd19 car and pd-1 knock out engineered t-cells
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (54)
Associazione Italiana Ematologia Oncologia Pediatrica
Badalona Hospital Germans Trias i Pujol
Canadian Immunization Research Network
Chinese Academy of Medical Sciences
Danish Child Cancer Foundation
German Federal Ministry of Education and Research
Huazhong University of Science and Technology
Huizhou People's Central Hospital
Organization Involved with Phase 3 Indications (148)
Aamu Pediatric Cancer Foundation
Acreditar - Associação de Pais e Amigos das Crianças com Cancro
Albert Einstein Israelite Hospital
Assistance Publique - Hôpitaux de Paris
Azienda Ospedaliera San Gerardo di Monza
Bangabandhu Sheikh Mujib Medical University
Blood and Marrow Transplant Clinical Trials Network
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
Changzhou No.2 People's Hospital
Children's Cancer and Leukaemia Group
Children's Cancer Group, China
Children's National Medical Center
Cohen Children's Medical Center of New York
Cook Children's Medical Center
Dutch Childhood Oncology Group
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
French Innovative Leukemia Organisation
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Grupo Português De Leucemias Pediátricas
Hoosier Cancer Research Network
Hospital Civil Juan I. Menchaca
Instituto de Investigacion de Cancer de la Infancia y la Adolescencia
Instituto de Investigacion en Cancer de la Infancia y la Adolescencia
Japan Adult Leukemia Study Group
Katholieke Universiteit Leuven
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
National Institutes of Health (NIH)
National University of Malaysia
Oregon Health and Science University
People's Liberation Army of China
Royal Marsden Hospital NHS Trust
San Jorge Children's Hospital, Puerto Rico
Shijiazhuang Pharma Group (CSPC)
Organization Involved with Phase 2 Indications (260)
Australian & New Zealand Childhood Hematology & Oncology Group
Azienda Ospedaliera Antonio Cardarelli
Azienda Osperdaliera Vincenzo Cervello Divisione
Bambino Gesù Hospital and Research Institute
Betta Pharmaceuticals Co.,Ltd.
Cancer and Leukemia Group B (CALGB)
Children's Hospital Los Angeles
Chinese University of Hong Kong
City of Hope National Medical Center
Colorado Blood Cancer Institute
Complessa di Ematologia and Dir Departmento
CZECRIN - Czech Clinical Research Infrastructure Network
Department of Health and Human Services
Department of Health, United Kingdom
Doris Duke Charitable Foundation
Federal University of Rio de Janeiro
Federal University of Rio Grande do Sul
First People's Hospital of Foshan
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Fundacao Hospital Amaral Carvalho
Gottfried Wilhelm Leibniz Universität Hannover
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Gruppo Italiano Malattie EMatologiche dell'Adulto
Guangdong Pharmaceutical University
Henan University of Traditional Chinese Medicine
Herbert Irving Comprehensive Cancer Center
Hospital de Clinicias da UICAMP
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Nossa Senhora da Conceicao
Hospital Santa Marcelina, Sao Paulo, Brasil
HOVON - Dutch Haemato-Oncology Association
Icahn School of Medicine at Mount Sinai
Infinity Pharmaceuticals, Inc.
Innovative Therapies For Children with Cancer Consortium
Institut de Cancérologie de la Loire (ICLN)
Institut de Cancerologie de l'Ouest Paul Papin
Institute of Hematology and Blood Transfusion, Czech Republic
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Português de Oncologia de Lisboa
Istituto Nazionale per lo Studio e la Cura dei Tumori
Istitutp di Ematologia ed Oncologia Medica
JP Moulton Charitable Foundation
Liberty Hematology and Oncology
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
National Hospital Organisation Nagoya Medical Centre
Our Lady's Chilrden's Hospital, Ireland
Pavlov First Saint Petersburg State Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rio de Janeiro Federal University
Santobono - Pausilipon Hospital
Service Clinique des Maladies du Sang
Shanghai Bioray Laboratory Inc.
Shanghai Children Medicine Center
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Institute for Innovation and Translational Medicine
Spanish Society of Pediatric Hematology and Oncology
State University of New York, Buffalo
Technical University of Dresden
The Beijing Pregene Science and Technology Company, Ltd.
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Korean Society of Pediatric Hematology Oncology
The Wayne D. Kuni and Joan E. Kuni Foundation
Tokyo Metropolitan Komagome Hospital
Universidad Autonoma de Madrid
Universidade Federal do Parana
Universita Degli Studi La Sapeinza
University of Alabama, Birmingham
University of British Columbia
University of California, Davis
University of California, Irvine
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of Roma La Sapienza
University of Southern California
U.O. di Ematologia- Ospedale dell'Angelo - Mestre
Organization Involved with Phase 1 Indications (99)
Alex's Lemonade Stand Foundation
Applied Physiology Research Center
Beijing Sanwater Biological Technology Co., Ltd.
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Cellular Biomedicine Group Ltd.
CLL Global Research Foundation
Nanjing Bioheng Biotech Co., Ltd.
National Comprehensive Cancer Network
Seyyed-alshohada hospital of Isfahan
Shanghai Longyao Biotechnology Inc., Ltd.
Shenzhen immune gene therapy research institute
South Plains Oncology Consortium
Swiss Pediatric Oncology Group
Organization Involved with Other Experimental Indications (13)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.